Alnylam And Roche Initiated KARDIA-3 Phase 2 Study Of Zilebesiran Used As An Add-on Therapy For High Cardiovascular Risk And Uncontrolled Hypertension Despite Treatment With Two To Four Standard Antihypertensive Medications
Author: Benzinga Newsdesk | March 05, 2024 08:42am